Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma

被引:0
作者
Ganessan Kichenadasse
Jim Henry Hughes
John O. Miners
Arduino A. Mangoni
Andrew Rowland
Ashley M. Hopkins
Michael J. Sorich
机构
[1] Flinders University,Department of Clinical Pharmacology, College of Medicine and Public Health
[2] Flinders Medical Centre/Flinders University,Department of Medical Oncology, Flinders Centre for Innovation in Cancer
[3] University of South Australia,undefined
来源
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词
Vemurafenib; Melanoma; Threshold concentration; Survival;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:615 / 620
页数:5
相关论文
共 50 条
[21]   S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma [J].
Abusaif, Sail ;
Jradi, Zeinab ;
Held, Laura ;
Pflugfelder, Annette ;
Weide, Benjamin ;
Meier, Friedegund ;
Garbe, Claus ;
Eigentler, Thomas K. .
MELANOMA RESEARCH, 2013, 23 (05) :396-401
[22]   Poorer survival outcomes in patients with multiple versus single primary melanoma [J].
Karapetyan, Lilit ;
Yang, Xi ;
Knight, Andrew D. ;
Huang, Ziyu ;
Wang, Hong ;
Sander, Cindy A. ;
Minnier, Christopher P. ;
Wilson, Melissa ;
Li, Aofei ;
Karunamurthy, Arivarasan ;
Storkus, Walter J. ;
Kirkwood, John M. .
CANCER, 2022, 128 (11) :2098-2106
[23]   Vemurafenib in Patients With BRAF V600E Mutation-Positive Advanced Melanoma [J].
Ravnan, Marcus C. ;
Matalka, Mazen S. .
CLINICAL THERAPEUTICS, 2012, 34 (07) :1474-1486
[24]   The relationship between hope, medical expenditure and survival among advanced cancer patients [J].
Chay, Junxing ;
Huynh, Vinh Anh ;
Cheung, Yin Bun ;
Kanesvaran, Ravindran ;
Lee, Lai Heng ;
Malhotra, Chetna ;
Finkelstein, Eric Andrew .
FRONTIERS IN PSYCHOLOGY, 2023, 14
[25]   A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients [J].
Alvarez, Jean-Claude ;
Funck-Brentano, Elisa ;
Abe, Emuri ;
Etting, Isabelle ;
Saiag, Philippe ;
Knapp, Adeline .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, 97 :29-32
[26]   NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib [J].
Parekh, Vishwas ;
Sobanko, Joseph ;
Miller, Christopher J. ;
Karakousis, Giorgos ;
Xu, Wei ;
Letrero, Richard ;
Elenitsas, Rosalie ;
Xu, Xiaowei ;
Elder, David E. ;
Amaravadi, Ravi ;
Schuchter, Lynn M. ;
Nathanson, Katherine L. ;
Wilson, Melissa A. ;
Chu, Emily Y. .
JOURNAL OF CUTANEOUS PATHOLOGY, 2019, 46 (03) :190-194
[27]   Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib [J].
Lewis, Karl ;
Hauschild, Axel ;
Larkin, James ;
Ribas, Antoni ;
Flaherty, Keith T. ;
McArthur, Grant A. ;
Dreno, Brigitte ;
McKenna, Edward ;
Zhu, Qian ;
Mun, Yong ;
Ascierto, Paolo A. .
EUROPEAN JOURNAL OF CANCER, 2019, 116 :45-55
[28]   Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 [J].
Hamid, O. ;
Robert, C. ;
Daud, A. ;
Hodi, F. S. ;
Hwu, W. J. ;
Kefford, R. ;
Wolchok, J. D. ;
Hersey, P. ;
Joseph, R. ;
Weber, J. S. ;
Dronca, R. ;
Mitchell, T. C. ;
Patnaik, A. ;
Zarour, H. M. ;
Joshua, A. M. ;
Zhao, Q. ;
Jensen, E. ;
Ahsan, S. ;
Ibrahim, N. ;
Ribas, A. .
ANNALS OF ONCOLOGY, 2019, 30 (04) :582-588
[29]   Treatment patterns and outcomes in patients with advanced melanoma in France [J].
Bedane, Christophe ;
Leccia, Marie-Therese ;
Sassolas, Bruno ;
Bregman, Bruno ;
Lebbe, Celeste .
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (10) :1297-1305
[30]   Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data [J].
Czirbesz, Kata ;
Gorka, Eszter ;
Balatoni, Timea ;
Panczel, Gitta ;
Melegh, Krisztina ;
Kovacs, Peter ;
Gezsi, Andras ;
Liszkay, Gabriella .
PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) :45-50